Biogen is a global biotechnology company pioneering in neuroscience. Founded in 1978, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is at the forefront of research for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
Serves as the central hub for global operations, research and development leadership, corporate strategy, and administrative functions.
State-of-the-art research laboratories and office spaces integrated within Kendall Square, known for its high concentration of biotech and pharmaceutical companies and academic institutions like MIT.
Characterized by a strong emphasis on scientific innovation, collaboration, patient-focus, and a fast-paced environment driven by the pursuit of breakthrough therapies.
The Cambridge headquarters is pivotal for Biogen's R&D strategy, fostering collaborations and attracting top scientific talent. Its location in a leading biotech ecosystem enhances innovation and industry partnerships.
Biogen supports a worldwide network encompassing research and development sites, advanced manufacturing facilities, and commercial operations in numerous countries. This global infrastructure enables the company to discover, develop, and deliver its innovative therapies to patients across North America, Europe, Asia, Latin America, and other regions.
225 Binney Street
Cambridge
Massachusetts
USA
Address: 5000 Davis Dr, Research Triangle Park, NC 27709, USA (Representative address, Biogen has multiple facilities in RTP)
Leverages the Research Triangle Park's rich biotech ecosystem, skilled workforce, and established infrastructure for pharmaceutical manufacturing and research.
Address: Attisholzstrasse 10, 4542 Luterbach, Switzerland
Serves as a strategic European manufacturing hub, ensuring supply chain resilience and access to advanced manufacturing technology and expertise in Europe.
Address: Neuhofstrasse 30, 6340 Baar, Switzerland
Acts as a central point for managing Biogen's diverse international markets, benefiting from Switzerland's central European location and established pharmaceutical industry presence.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biogen' leadership includes:
Biogen has been backed by several prominent investors over the years, including:
Over the past year, Biogen has experienced notable executive transitions, including key appointments to its leadership team in areas like Development and Corporate Development, alongside a strategic reorganization of its commercial leadership. These changes reflect the company's ongoing evolution under new CEO Christopher A. Viehbacher and its focus on advancing its neuroscience pipeline and commercial strategy. Several departures of senior executives have also occurred during this period of transformation.
Discover the tools Biogen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biogen commonly uses the firstname.lastname email format for its employees. Variations might exist, but this is the most frequently observed pattern.
firstname.lastname@biogen.com
Format
jane.doe@biogen.com
Example
90%
Success rate
Biogen Investor Relations • May 7, 2024
Biogen reported promising early-stage clinical trial data for BIIB105, an investigational antisense oligonucleotide (ASO) therapy for Angelman syndrome, indicating improvements in multiple areas of clinical development for patients....more
Biogen Investor Relations • April 24, 2024
Biogen announced its Q1 2024 financial results, exceeding profit expectations due to cost management and increasing sales of its Alzheimer's drug, Leqembi. The company reaffirmed its full-year financial guidance....more
Biogen Investor Relations • March 12, 2024
Biogen announced its definitive agreement to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments. The acquisition aims to enhance Biogen's immunology pipeline, notably with felzartamab, a late-stage candidate for rare immune diseases....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biogen, are just a search away.